↓ Skip to main content

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development

Overview of attention for article published in Cancer Cell, July 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

news
7 news outlets
twitter
47 X users
patent
1 patent

Citations

dimensions_citation
131 Dimensions

Readers on

mendeley
198 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development
Published in
Cancer Cell, July 2018
DOI 10.1016/j.ccell.2018.06.006
Pubmed ID
Authors

Zev A. Binder, Amy Haseley Thorne, Spyridon Bakas, E. Paul Wileyto, Michel Bilello, Hamed Akbari, Saima Rathore, Sung Min Ha, Logan Zhang, Cole J. Ferguson, Sonika Dahiya, Wenya Linda Bi, David A. Reardon, Ahmed Idbaih, Joerg Felsberg, Bettina Hentschel, Michael Weller, Stephen J. Bagley, Jennifer J.D. Morrissette, MacLean P. Nasrallah, Jianhui Ma, Ciro Zanca, Andrew M. Scott, Laura Orellana, Christos Davatzikos, Frank B. Furnari, Donald M. O'Rourke

Abstract

We explored the clinical and pathological impact of epidermal growth factor receptor (EGFR) extracellular domain missense mutations. Retrospective assessment of 260 de novo glioblastoma patients revealed a significant reduction in overall survival of patients having tumors with EGFR mutations at alanine 289 (EGFRA289D/T/V). Quantitative multi-parametric magnetic resonance imaging analyses indicated increased tumor invasion for EGFRA289D/T/V mutants, corroborated in mice bearing intracranial tumors expressing EGFRA289V and dependent on ERK-mediated expression of matrix metalloproteinase-1. EGFRA289V tumor growth was attenuated with an antibody against a cryptic epitope, based on in silico simulation. The findings of this study indicate a highly invasive phenotype associated with the EGFRA289V mutation in glioblastoma, postulating EGFRA289V as a molecular marker for responsiveness to therapy with EGFR-targeting antibodies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 47 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 198 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 198 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 34 17%
Student > Ph. D. Student 31 16%
Student > Bachelor 25 13%
Student > Master 16 8%
Student > Doctoral Student 12 6%
Other 27 14%
Unknown 53 27%
Readers by discipline Count As %
Medicine and Dentistry 44 22%
Biochemistry, Genetics and Molecular Biology 36 18%
Engineering 9 5%
Agricultural and Biological Sciences 9 5%
Computer Science 9 5%
Other 30 15%
Unknown 61 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 76. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2021.
All research outputs
#559,217
of 25,385,509 outputs
Outputs from Cancer Cell
#401
of 3,149 outputs
Outputs of similar age
#12,207
of 341,606 outputs
Outputs of similar age from Cancer Cell
#12
of 40 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,149 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.3. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,606 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.